NCT00290472|CompletedPhase 2Results
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
A Phase II Study of CCI-779 in B-cell Lymphoma and CLL
Loading search results
Sponsor study identifier
Secondary identifiers
REGISTRY · CTRP (Clinical Trial Reporting Program)
OTHER · University of Chicago
OTHER · CTEP
NIH
NIH
NIH
interventional
89
1 country
13
Study Start
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
April 2010
Actual (reported)Study Completion
April 2010
Actual (reported)Drugs used in chemotherapy, such as CCI-779, work in different ways to stop cancer cells from dividing so they stop growing or die. This phase II trial is studying how well CCI-779 works in treating patients with recurrent or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2010
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
February 10, 2006
Actual (reported)February 13, 2006
Actual (reported)April 2010
Actual (reported)April 2010
Actual (reported)February 11, 2014
Actual (reported)Objective Overall Response Rate
The 1999 international response criteria (http://www.ncbi.nlm.nih.gov/pubmed/10655437#) as published by Cheson was used for the definition of target lesions and CT scans were used for response assessment. CR(complete response)/CRu(unconfirmed complete response) requires disappearance of all target lesions; PR (partial response) requires \>=50% decrease in the sum of the products of the greatest diameters; Overall Response (OR)=CR/CRu+PR.
Up to 6 years
Duration of Response
Duration of response was the time from date of response to date of progression and evaluated among participants with response. According to the 1999 international response criteria as published by Cheson, progression/progressive disease is defined as \>=50% increase from nadir in the sum of the products of the greatest diameters of any previously identified abnormal node for PRs or nonresponders, or appearance of any new lesion during or at the end of therapy.
Up to 6 years
Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 8 weeks.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University of Chicago
Chicago, Illinois, 60637, United States
Decatur Memorial Hospital
Decatur, Illinois, 62526, United States
Evanston Hospital CCOP
Evanston, Illinois, 60201, United States
Ingalls Memorial Hospital
Harvey, Illinois, 60426, United States
Adventist La Grange Memorial Hospital
La Grange, Illinois, 60525, United States
Loyola University Medical Center
Maywood, Illinois, 60153, United States
Central Illinois Hematology Oncology Center
Springfield, Illinois, 60702, United States
Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 1;28(31):4740-6. doi: 10.1200/JCO.2010.29.2813. Epub 2010 Sep 13.
Sonali Smith
University of Chicago
89 participants (actual enrollment reported by the registry).
First Submitted
February 10, 2006
First Posted
February 13, 2006
Study Start
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
Overall Survival
The overall survival was evaluated using the Kaplan-Meier estimator.
Up to 6 years
Contact the study team to confirm eligibility.
Fort Wayne Medical Oncology and Hematology Inc-Parkview
Fort Wayne, Indiana, 46845, United States
Northern Indiana Cancer Research Consortium
South Bend, Indiana, 46601, United States
University of Iowa
Iowa City, Iowa, 52242, United States
Oncology Care Associates PLLC
Saint Joseph, Michigan, 49085, United States
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Primary Completion
April 2010
Actual (reported)Study Completion
April 2010
Actual (reported)Last Updated
May 23, 2014
Results First Posted
February 11, 2014
Record last verified: 2013-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: